PGE2 Generation in Myocardium from Isolated Rat Atrium under Hypoxia and Reoxygenation Conditions. Effect of Anti-β1 IgG from Patients with Chronic Severe Periodontitis


Background: Hypoxia is one of the most frequently encountered stresses in health and disease. Methods: We compared the effects of an anti-β1 periodontal IgG (pIgG) and an authentic β1 adrenergic agonist, xamoterol, on isolated myocardium from rat atria contractility. We used an ELISA assay to measure the generation of PGE2 in vitro after the addition of either the antibody or the adrenergic agonist. We analyzed the myocardium histopathologically in the presence of both the antibody and/or the adrenergic agonist drug during normoxia, hypoxia and reperfusion conditions. Results: PGE2 generation increased during the hypoxia and was unchanged during reoxygenation period compared with the production of this prostanoid in atria during normoxia condition. A β1 specific adrenoceptor antagonist atenolol and the β1 synthetic peptide abrogated the increment of the prostanoid in the presence of pIgG but only atenolol due to it in the presence of xamoterol. The increment of PGE2 was dependent on the activation of cox-1 and cox-2 isoforms. Moreover, cox-2 was more active and produced more increments in the production of PGE2 in the presence of the pIgG than cox-1 activation. Histopathologically, studies of myocardium specimens during these different periods of the experimental protocol: basal (B), hypoxia (H) and reoxygenation (R), were also performed and showed tissue necrosis and edematization at the myocardium level. Conclusion: The phenomenon studied here supports the notion that PGE2 may be responsible for tissue edematization. PGE2 maybe acts as a beneficial modulator in the myocardium and prevents a major injury of it. The inflammation damage to the heart organ and cardiomyocytes caused by the actions of the antibodies in the course of heart lesions provoked by cardiovascular autoimmune disease, explains some of these results obtained in the present experiments. Further studies will be needed to establish the real role of PGE2 during hypoxia injury of the heart in the course of autoimmune diseases.

Share and Cite:

S. Ganzinelli, S. Reina, M. Matoso, G. González, C. Morales and E. Borda, "PGE2 Generation in Myocardium from Isolated Rat Atrium under Hypoxia and Reoxygenation Conditions. Effect of Anti-β1 IgG from Patients with Chronic Severe Periodontitis," Pharmacology & Pharmacy, Vol. 5 No. 2, 2014, pp. 204-215. doi: 10.4236/pp.2014.52027.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. V. Serebrovskaya, R. J. Swanson and E. E. Kolesnikova, “Intermittent Hypoxia: Mechanisms of Action and Some Applications to Bronchial Asthma Treatment,” Journal of Physiology and Pharmacology, Vol. 54, No. Suppl. 1, 2003, pp. S35-S41.
[2] J. A. Neubauer, “Physiological and Pathophysiological Responses to Intermittent Hypoxia,” Journal of Apply Physiology, Vol. 90, No. 4, 2001, pp. 1593-1599.
[3] N. R. Prabhakar and G. K. Kumar, “Oxidative Stress in the Systemic and Cellular Responses to Intermittent Hypoxia,” Biological Chemistry, Vol. 385, No. 3-4, 2004, pp. 217-221.
[4] B. W. Row, L. Kheirandish, J. J. Neville and D. Gozal, “Impaired Spatial Learning and Hyperactivity in Developing Rats Exposed to Intermittent Hypoxia,” Pediatric Research, Vol. 52, No. 3, 2002, pp. 449-453.
[5] Z. Cai, D. J. Manalo, G. Wei, E. R. Rodriguez, K. FoxTalbot, J. L. Lu, H. Zweier and G. L. Semenza, “Hearts from Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected against Ischemia-Reperfusion Injury,” Circulation, Vol. 108, No. 1, 2003, pp. 79-85.
[6] N. A. Agadzhanyan and A. Y. Katkov, “Ways of Increasing Human Resistance to Acute Hypoxia,” Human Physiology, Vol. 9, No. 4, 1983, pp. 217-223.
[7] J. C. LaManna, J. C. Chavez and P. Pichiule, “Structural and Functional Adaptation to Hypoxia in the Rat Brain,” Journal of Experimental Biology, Vol. 207, No. 18, 2004, pp. 3163-3169.
[8] L. D. Lukyanova, “Novel Approach to Understanding of Molecular Mechanisms of Adaptation to Hypoxia,” In: A. Hargens, N. Takeda and P. K. Singal, Eds., Adaptation Biology and Medicine, New Deli, Vol. 4, 2005, pp. 1-19.
[9] M. Burtscher, O. Pachinger, I. Ehrenbourg, G. Mitterbauer, M. Faulhaber, R. Pühringer and E. Tkatchouk, “Intermittent Hypoxia Increases Exercise Tolerance in Elderly Men with and without Coronary Artery Disease,” International Journal of Cardiology, Vol. 96, No. 2, 2004, pp. 247-254.
[10] T. D. Sabdanbekov, “Effect of Hypoxic Training on Clinico-Hemodynamic Indices and Physical Work Capacity of Patients with Large-Focus Myocardial Infarct,” Kardiologiia, Vol. 27, No. 12, 1987, pp. 59-62.
[11] O. M. Andriankaja, R. J. Genco, J. Dorn, J. Dmochowski, K. Hovey, K. L. Falkner and M. Trevisan, “Periodontal Disease and Risk of Myocardial Infarction: The Role of Gender and Smoking,” European Journal of Epidemiology, Vol. 22, No. 10, 2007, pp. 699-705.
[12] F. Cairo, S. Castellani, A. M. Gori, M. Nieri, G. Baldelli, R. Abbate and G. P. Pini-Prato, “Severe Periodontitis in Young Adults Is Associated with Sub-Clinical Atherosclerosis,” Journal of Clinical of Periodontology, Vol. 35, No. 6, 2008, pp. 465-472.
[13] L. L. Humphrey, R. Fu, D. I. Buckley, M. Freeman and M. Helfand, “Periodontal Disease and Coronary Heart Disease Incidence: A Systematic Review and Meta-Analysis,” Journal of General Internal Medicine, Vol. 23, No. 12, 2008, pp. 2079-2086.
[14] M. Segovia, S. Ganzinelli, S. Reina, E. Borda and L. Sterin-Borda, “Role of Anti-β1 Adrenergic Antibodies from Patients with Periodontitis in Cardiac Dysfunction,” Journal of Oral Patholology & Medicine, Vol. 41, No. 3, 2012, pp. 242-248.
[15] M. Segovia, S. Reina, E. Borda and L. Sterin-Borda, “Autoantibodies to the β1-Adrenoceptor from Patients with Periodontitis as a Risk Factor for Cardiac Dysfunction,” International Scholarly Research Network Dentistry, 2011, Article ID: 791393.
[16] M. Goppelt-Struebe, “Regulation of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozyme Expression,” Prostaglandins, Leukotrienes and Essential Fatty Acids, Vol. 52, No. 6, 1995, pp. 213-222.
[17] W. L. Smith, and R. Langenbach, “Why There Are Two Cyclooxygenase Isozymes,” Journal Clinical Investigation, Vol. 107, No. 6, 2001, pp. 1491-1495.
[18] S. Gottlieb, “COX 2 Inhibitors May Increase Risk of Heart Attack,” British Medical Journal, Vol. 323, No. 7311, 2001, pp. 471-472.
[19] K. H. Pitkala, T. E. Strandberg and R. S. Tilvis, “Worsening Heart Failure Associated with COX-2 Inhibitors,” American Journal of Medicine, Vol. 112, No. 5, 2002, pp. 424-426.
[20] K. Shinmura, X. L. Tang, Y. Wang, Y. T. Xuan, S. Q. Liu, H. Takano, A. Bhatnagar and R. Bolli, “Cyclooxygenase-2 Mediates the Cardioprotective Effects of the Late Phase of Ischemic Preconditioning in Conscious Rabbits,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 18, 2000, pp. 10197-10202.
[21] X. Yang, K. K. Sheares, N. Davie, P. D. Upton, G. W. Taylor, J. Horsley, J. Wharton and N. W. Morrell, “Hypoxic Induction of Cox-2 Regulates Proliferation of Human Pulmonary Artery Smooth Muscle Cells,” American Journal of Respiratory Cell and Molecular Biology, Vol. 27, No. 6, 2002, pp. 688-696.
[22] R. Bolli, K. Shinmura, X. L. Tang, E. Kodani, Y. T. Xuan, Y. Guo and B. Dawn, “Discovery of a New Function of Cyclooxygenase (COX)-2: COX-2 Is a Cardioprotective Protein That Alleviates Ischemia/Reperfusion Injury and Mediates the Late Phase of Preconditioning,” Cardiovascular Research, Vol. 55, No. 3, 2002, pp. 506-519.
[23] G. Wu G, A. P. Mannam, J. Wu, S. Kirbis, J. L. Shie, C. Chen, R. J. Laham, F. W. Sellke and J. Li, “Hypoxia Induces Myocyte-Dependent COX-2 Regulation in Endothelial Cells: Role of VEGF,” American Journal of Physiology Heart Circulation Physiology, Vol. 285, No. 6, 2003, pp. H2420-H2429.
[24] L. Sterin-Borda, P. M. Cossio, M. F. Gimeno, A. L. Gimeno, C. Diez, R. P. Laguens, P. C. Meckert and R. M. Arana, “Effect of Chagasic Sera on the Rat Isolated Atrial Preparation: Immunological, Morphological and Function Aspects,” Cardiovascular Research, Vol. 10, No. 6, 1976, pp. 613-622.
[25] P. Zong, S. Setty, W. Sun, R. Martinez, J. D. Tune, I. V. Ehrenbourg, E. N. Tkatchouk, R. T. Mallet and H. F. Downey, “Intermittent Hypoxic Training Protects Canine Myocardium from Infarction,” Experimental Biology and Medicine (Maywood, N.J.), Vol. 229, No. 8, 2004, pp. 806-812.
[26] B. Zamorano, “Subcellular Localization of Prostaglandin-E3 in Rat Heart Tissue,” Cardiovascular Drugs & Therapeutics, Vol. 5, No. 3, 1991, pp. 655-657.
[27] H. A. Peredo, E. J. Filinger, S. Sanguinetti, P. S. Lorenzo and E. Adler-Graschinsky, “Prostanoid Production in Hypoxic Rat Isolated Atria: Influence of Acute Diabetes,” Prostaglandins Leukot Essent Fatty Acids, Vol. 51, No. 4, 1994, pp. 231-234.
[28] R. Rösen, P. Rösen, R. Ohlendorf and K. Schrör, “Prostacyclin Prevents Ischemia-Induced Increase of Lactate and Cyclic AMP in Ischemic Myocardium,” European Journal of Pharmacology, Vol. 69, No. 4, 1981, pp. 489-491.
[29] S. C. Wong, M. Fukuchi, P. Melnyk, I. Rodger and A. Giaid, “Induction of Ciclooxygenase 2 and Activation of Nuclear Factor-kappa B in Myocardium of Patients with Congestive Heart Failure,” Circulation, Vol. 98, No. 2, 1998, pp. 100-103.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.